Comparable stake leader
FMR LLC
SEC ownership of Nuvation Bio Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001811063.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- NUVB on NYSE
- Parsed ownership sources
-
13F and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001811063
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Nuvation Bio Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
BlackRock, Inc.
6.4%
Decheng Capital LLC
7.7%
VANGUARD CAPITAL MANAGEMENT LLC
3.4%
Omega Fund Management, LLC
2.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$223,035,355
51,989,593 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.4%
from 13D/G
|
$107,680,605
25,100,374 shares
|
— | 31 Mar 2026 |
| Decheng Capital LLC |
13F
Company
|
7.7%
|
$111,344,543
25,954,439 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.4%
|
$49,876,389
11,626,198 shares
|
— | 31 Mar 2026 |
| Omega Fund Management, LLC |
13F
Company
|
2.4%
|
$34,667,872
8,081,089 shares
|
— | 31 Mar 2026 |
| Laurion Capital Management LP |
13F
Company
|
2.3%
|
$33,559,117
7,822,638 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
2%
|
$29,107,337
6,784,927 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.7%
|
$25,160,269
5,863,654 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$8,852,966.
Buys
$118,250
Insiders: 1
Sells
$8,971,216
Insiders: 6
Net
-$8,852,966
Shares: -1,386,469
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 25,000
Shares: 1,411,469
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 25,000 | 235,668 | $118,250 | $1,418,748 | -$1,300,498 |
| 3-6 | 0 | 286,750 | $0 | $1,338,839 | -$1,338,839 |
| 6-9 | 0 | 789,051 | $0 | $5,711,168 | -$5,711,168 |
| 9-12 | 0 | 100,000 | $0 | $502,460 | -$502,460 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to Nuvation Bio Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
Omega Fund V, L.P.
Net 12M change
-$8,852,967
Latest report
15 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Omega Fund V, L.P. | 10%+ Owner | $114,561,104 | Filing P/S | 05 Apr 2022 | ||
| David Hung | PRESIDENT AND CEO, Director, 10%+ Owner | $105,935,243 | Filing P/S | 27 Feb 2026 | ||
| Junyuan Jerry Wang | CEO, ANHEART THERAPEUTICS LTD., Director | $17,665,663 | Mixed | 11 Nov 2024 | ||
| Oleg Nodelman | Director | $17,251,636 | Filing P/S | 19 Sep 2023 | ||
| Daniel G. Welch | Director | $1,082,313 | Mixed | 24 May 2024 | ||
| Robert Mashal | Director | $1,064,250 | +$118,250 | +12% | Filing P/S | 09 Jun 2026 |
| Dongfang Liu | Chief Medical Officer | $1,021,559 | -$1,867,357 | -65% | Mixed | 17 Apr 2026 |
| Kim D. Blickenstaff | Director | $500,089 | Filing P/S | 21 May 2026 | ||
| Colleen Sjogren | Chief Commercial Officer | $486,360 | Mixed | 27 Feb 2026 | ||
| Moses Makunje | Title: VP, Finance and principal financial and accounting officer. | $394,513 | Mixed | 27 Feb 2026 | ||
| Kerry Wentworth | Chief Regulatory Officer | $319,001 | -$1,467,030 | -82% | Filing P/S | 23 Jun 2026 |
| Philippe Sauvage | Chief Financial Officer | $307,464 | -$286,370 | -48% | Median | 15 Jul 2026 |
| Stacy Markel | Chief People Officer | $196,377 | -$753,188 | -79% | Filing P/S | 23 Jun 2026 |
| David C. Hanley | Chief Technical Operations | $171,321 | -$1,427,680 | -89% | Filing P/S | 27 Feb 2026 |
| Jennifer A. Fox | Chief Financial Officer | $6,099 | Mixed | 28 Feb 2023 | ||
| Gary Hattersley | Chief Scientific Officer | $0 | -$3,169,592 | -100% | Mixed | 27 Feb 2026 |
| Kathryn E. Falberg | Director | Mixed | 21 May 2026 | |||
| W. Anthony Vernon | Director | Mixed | 21 May 2026 | |||
| Robert B. Bazemore | Director | Mixed | 21 May 2026 | |||
| Xiangmin Cui | Director | Mixed | 21 May 2026 |
Recent insider transactions for Nuvation Bio Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Philippe Sauvage | NUVB | Class A Common Stock | Options Exercise | 283.1% | 40,000 | 54,131 | 15 Jul 2026 | Direct | ||
| Philippe Sauvage | NUVB | Stock Option (Right to Buy) | Options Exercise | -7.41% | -40,000 | 499,999 | 15 Jul 2026 | Direct | ||
| Stacy Markel | NUVB | Class A Common Stock | Sale | -79.3% | $753,188 | $6.03 | -125,000 | 32,591 | 23 Jun 2026 | Direct |
| Stacy Markel | NUVB | Class A Common Stock | Options Exercise | 383.5% | 125,000 | 157,591 | 23 Jun 2026 | Direct | ||
| Stacy Markel | NUVB | Stock Option (Right to Buy) | Options Exercise | -36.2% | -125,000 | 220,190 | 23 Jun 2026 | Direct | ||
| Kerry Wentworth | NUVB | Class A Common Stock | Sale | -54.3% | $379,191 | $6.02 | -63,000 | 53,000 | 23 Jun 2026 | Direct |
| Kerry Wentworth | NUVB | Class A Common Stock | Options Exercise | 118.9% | 63,000 | 116,000 | 23 Jun 2026 | Direct | ||
| Kerry Wentworth | NUVB | Stock Option (Right to Buy) | Options Exercise | -29.3% | -63,000 | 152,250 | 23 Jun 2026 | Direct | ||
| Philippe Sauvage | NUVB | Class A Common Stock | Sale | -79% | $286,370 | $6.01 | -47,668 | 12,673 | 23 Jun 2026 | Direct |
| Philippe Sauvage | NUVB | Class A Common Stock | Options Exercise | 376.1% | 47,668 | 60,341 | 23 Jun 2026 | Direct | ||
| Philippe Sauvage | NUVB | Stock Option (Right to Buy) | Options Exercise | -6.36% | -47,668 | 702,332 | 23 Jun 2026 | Direct | ||
| Robert Mashal | NUVB | Class A Common Stock | Purchase | 12.5% | $118,250 | $4.73 | 25,000 | 225,000 | 09 Jun 2026 | By Trust |
| W. Anthony Vernon | NUVB | Stock Option (Right to Buy) | Award | 123,397 | 123,397 | 21 May 2026 | Direct | |||
| Robert Mashal | NUVB | Stock Option (Right to Buy) | Award | 123,397 | 123,397 | 21 May 2026 | Direct | |||
| Kathryn E. Falberg | NUVB | Stock Option (Right to Buy) | Award | 123,397 | 123,397 | 21 May 2026 | Direct | |||
| Kim D. Blickenstaff | NUVB | Stock Option (Right to Buy) | Award | 123,397 | 123,397 | 21 May 2026 | Direct | |||
| Robert B. Bazemore | NUVB | Stock Option (Right to Buy) | Award | 123,397 | 123,397 | 21 May 2026 | Direct | |||
| Xiangmin Cui | NUVB | Stock Option (Right to Buy) | Award | 123,397 | 123,397 | 21 May 2026 | Direct | |||
| Kerry Wentworth | NUVB | Class A Common Stock | Sale | -41% | $184,279 | $5.01 | -36,750 | 53,000 | 17 Apr 2026 | Direct |
| Kerry Wentworth | NUVB | Class A Common Stock | Options Exercise | 69.3% | 36,750 | 89,750 | 17 Apr 2026 | Direct | ||
| Kerry Wentworth | NUVB | Stock Option (Right to Buy) | Options Exercise | -14.6% | -36,750 | 215,250 | 17 Apr 2026 | Direct | ||
| Dongfang Liu | NUVB | Class A Common Stock | Sale | -73.5% | $251,000 | $5.02 | -50,000 | 18,000 | 17 Apr 2026 | Direct |
| Dongfang Liu | NUVB | Class A Common Stock | Options Exercise | 277.8% | 50,000 | 68,000 | 17 Apr 2026 | Direct | ||
| Dongfang Liu | NUVB | Stock Option (Right to Buy) | Options Exercise | -10.4% | -50,000 | 430,000 | 17 Apr 2026 | Direct | ||
| Kerry Wentworth | NUVB | Class A Common Stock | Sale | -79% | $903,560 | $4.52 | -200,000 | 53,000 | 06 Apr 2026 | Direct |
| Kerry Wentworth | NUVB | Class A Common Stock | Options Exercise | 377.4% | 200,000 | 253,000 | 06 Apr 2026 | Direct | ||
| Kerry Wentworth | NUVB | Stock Option (Right to Buy) | Options Exercise | -40% | -200,000 | 300,000 | 06 Apr 2026 | Direct | ||
| Xiangmin Cui | NUVB | Stock Option (Right to Buy) | Award | 76,923 | 76,923 | 27 Feb 2026 | Direct | |||
| Dongfang Liu | NUVB | Stock Option (Right to Buy) | Award | 748,130 | 748,130 | 27 Feb 2026 | Direct | |||
| Moses Makunje | NUVB | Class A Common Stock | Award | 292.1% | 50,761 | 68,137 | 27 Feb 2026 | Direct | ||
| Moses Makunje | NUVB | Stock Option (Right to Buy) | Award | 224,439 | 224,439 | 27 Feb 2026 | Direct | |||
| Kerry Wentworth | NUVB | Stock Option (Right to Buy) | Award | 748,130 | 748,130 | 27 Feb 2026 | Direct | |||
| Colleen Sjogren | NUVB | Stock Option (Right to Buy) | Award | 748,130 | 748,130 | 27 Feb 2026 | Direct | |||
| Philippe Sauvage | NUVB | Stock Option (Right to Buy) | Award | 748,130 | 748,130 | 27 Feb 2026 | Direct | |||
| Stacy Markel | NUVB | Stock Option (Right to Buy) | Award | 748,130 | 748,130 | 27 Feb 2026 | Direct | |||
| Gary Hattersley | NUVB | Stock Option (Right to Buy) | Award | 748,130 | 748,130 | 27 Feb 2026 | Direct | |||
| David C. Hanley | NUVB | Stock Option (Right to Buy) | Award | 748,130 | 748,130 | 27 Feb 2026 | Direct | |||
| David Hung | NUVB | Stock Option (Right to Buy) | Award | 1,995,012 | 1,995,012 | 27 Feb 2026 | Direct | |||
| Dongfang Liu | NUVB | Class A Common Stock | Sale | -89.3% | $1,173,255 | $7.82 | -150,000 | 18,000 | 01 Dec 2025 | Direct |
| Dongfang Liu | NUVB | Class A Common Stock | Options Exercise | 833.3% | 150,000 | 168,000 | 01 Dec 2025 | Direct | ||
| Dongfang Liu | NUVB | Stock Option (Right to Buy) | Options Exercise | -47.6% | -150,000 | 165,000 | 01 Dec 2025 | Direct | ||
| Dongfang Liu | NUVB | Class A Common Stock | Sale | -35.7% | $80,000 | $8.00 | -10,000 | 18,000 | 26 Nov 2025 | Direct |
| Dongfang Liu | NUVB | Class A Common Stock | Options Exercise | 55.6% | 10,000 | 28,000 | 26 Nov 2025 | Direct | ||
| Dongfang Liu | NUVB | Stock Option (Right to Buy) | Options Exercise | -2.08% | -10,000 | 470,000 | 26 Nov 2025 | Direct | ||
| Dongfang Liu | NUVB | Class A Common Stock | Sale | -35.7% | $75,000 | $7.50 | -10,000 | 18,000 | 25 Nov 2025 | Direct |
| Dongfang Liu | NUVB | Class A Common Stock | Options Exercise | 55.6% | 10,000 | 28,000 | 25 Nov 2025 | Direct | ||
| Dongfang Liu | NUVB | Stock Option (Right to Buy) | Options Exercise | -2.04% | -10,000 | 480,000 | 25 Nov 2025 | Direct | ||
| Gary Hattersley | NUVB | Class A Common Stock | Sale | -100% | $2,667,132 | $7.23 | -369,051 | 0 | 20 Nov 2025 | Direct |
| Gary Hattersley | NUVB | Class A Common Stock | Options Exercise | 369,051 | 300,000 | 20 Nov 2025 | Direct | |||
| Gary Hattersley | NUVB | Stock Option (Right to Buy) | Options Exercise | -64.8% | -369,051 | 200,000 | 20 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.